PT-112


Associated tags: Therapy, Pharmaceutical industry, Patient, Cancer, ICD, NCI, Research, National Cancer Institute, Safety, Immunogenic cell death, Vaccine, Promontory, Development of the human body, César Award for Best Poster, Orphan drug, Trial of the century, Merck Serono, Congress, Platinum, AACR

Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects

Retrieved on: 
Saturday, November 4, 2023
Society for Immunotherapy of Cancer, Mitochondrion, Immunogenic cell death, ICD, Bax, Northern blot, Doctor of Philosophy, Phosphorylation, Bcl-2, SITC, Cancer immunotherapy, Immunotherapy, Reactive oxygen species, ISR, Research and development, Cancer, Flow cytometry, Annual general meeting, Weill Cornell Medicine, Lung cancer, Endoplasmic reticulum, Society, Therapy, Patient, Cytosol, DNA, Vaccine, Platinum, Research

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death (ICD) in cancer cells. Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.

Key Points: 
  • Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism.
  • The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
  • PT-112 effects on mitochondria included increases in mitochondrial mass and reactive oxygen species, changes in membrane polarization, and the release of mitochondrial DNA into the cytosol, a potent immunogenic signal.
  • For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
European Organisation for Research and Treatment of Cancer, Treatment, Research and development, RNA, AACR, International Conference on Defects in Semiconductors, Baylor College of Medicine, EORTC, National Cancer Institute, Non-small-cell lung cancer, American Association for Cancer Research, Therapy, NCI, Gene, Prostate cancer, Prostate, Small RNA, Baylor University, Promontory, Conference, ICD, Pharmaceutical industry, Platinum, Vaccine, Doctor of Philosophy, Cancer, Research

NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.

Key Points: 
  • The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
  • Researchers also conducted nascent RNA sequencing in human cancer cells (non-small cell lung, prostate and renal cell carcinoma) following one and six hours of PT-112 treatment.
  • "While further validation of these findings is ongoing, this work deepens our understanding of PT-112's specific molecular effects.
  • PT-112 rapidly causes ribosomal biogenesis (RiBi) inhibition and nucleolar stress, likely driving previously observed PT-112-induced cancer organelle stresses and ICD.

Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting

Retrieved on: 
Friday, June 2, 2023
Thermal power stations in Russia and Soviet Union, Lead, Bangladesh Technical Education Board, ASCO, Thymoma, National Cancer Institute, American Society of Clinical Oncology, Patient, Annual general meeting, Thymic carcinoma, Therapy, NCI, Society, Safety, Pharmaceutical industry, MD

The trial is being conducted under formal collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (see NCT05104736 ).

Key Points: 
  • The trial is being conducted under formal collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (see NCT05104736 ).
  • The data were published online in an abstract for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • "Based on preliminary data to date, PT-112 appears to be safe and tolerable, and clinically active in patients with recurrent TETs.
  • The initial translational evidence of PT-112 immune activation is encouraging and supportive of further investigation," said Promontory Therapeutics Chief Medical Officer Johan Baeck, MD.

Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022

Retrieved on: 
Wednesday, November 30, 2022
NCI, Immunogenic cell death, NSCLC, Cancer, Merck Group, Safety, Large-cell lung carcinoma, Therapy, Patient, Damage-associated molecular pattern, Tumor microenvironment, Oncology, Abstract (summary), Orphan drug, Trial of the century, ICD, ESMO, ASH, César Award for Best Poster, CET, B cell, Research, Congress, Development of the human body, Merck Serono, European Society for Medical Oncology, Avelumab, Pharmaceutical industry

Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.

Key Points: 
  • Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
  • Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
  • PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.

Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
Independent Greeks, ASH, Merck Serono, Biochemistry, Congress, American Association for Cancer Research, Therapy, Patient, B cell, European Organisation for Research and Treatment of Cancer, Research, Promontory, Orphan drug, University, ICD, Treatment, Tumor microenvironment, Trial of the century, AACR, NSCLC, Doctor of Philosophy, National Cancer Institute, Department, Mitochondrion, American Association, Development of the human body, CEST, EORTC, Patent, Prostate cancer, Safety, Merck Group, National, ESMO, Immunogenic cell death, Reactive oxygen species, Damage-associated molecular pattern, César Award for Best Poster, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Platinum, Vaccine, Medical imaging, Cancer

"Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.

Key Points: 
  • "Ongoing studies into PT-112's ability to induce immunogenic cell death and cancer cell organelle stresses have been encouraging and support our elucidation of the drivers of PT-112's validated immunogenic cancer cell death," said Promontory co-founder and Chief Operating Officer Matthew Price.
  • The non-clinical study of PT-112 was designed to continue the characterization of PT-112's effects on mitochondria in a panel of human prostate cancer cell lines.
  • Key study findings included:
    Human prostate cancer cell lines exhibited differential metabolic features when compared to the healthy prostate cell line RWPE-1.
  • After brief durations of PT-112 exposure, electron microscopy revealed noteworthy changes in prostate cancer cell mitochondrial structure in response to PT-112.

Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent

Retrieved on: 
Thursday, October 20, 2022
Merck Serono, ASH, Congress, Therapy, ENA, Patient, B cell, Drug resistance, Research, Promontory, Orphan drug, ICD, Tumor microenvironment, Trial of the century, AACR, NSCLC, Development of the human body, National Cancer Institute, United States Patent and Trademark Office, Patent, Immunotherapy, Safety, Merck Group, National, ESMO, Immunogenic cell death, Damage-associated molecular pattern, César Award for Best Poster, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Cancer

"This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."

Key Points: 
  • "This U.S. patent issuance underscores our approach to oncologic small molecule immunotherapies along with our robust clinical pipeline assessing PT-112 alone and in immunotherapy combination."
  • The patent, titled "Phosphaplatin Compounds as Immuno-Modulatory Agents and Therapeutic Uses Thereof," was issued on Sept. 13, 2022 as U.S. Patent No.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.
  • To learn more about Promontory Therapeutics, visit the company's website here .